NewGenIvf swings to $8.08M net loss in H1 2026

NIVF reported an operating loss of $3,547,412 for the six months ended June 30, 2026, versus $3,240,376 in 2025.

Rhea-AI Filing Summary

NewGenIvf Group Ltd reported unaudited results for the six months ended June 30, 2026, with revenue of $1,924,881, compared with $2,019,628 for the six months ended June 30, 2025. Gross profit was $464,488, compared with $313,804. The company reported a net loss of $8,079,392, versus net income of $698,032; net loss attributable to the company’s shareholders was $8,035,306, compared with net income attributable to shareholders of $724,975.

As of June 30, 2026, cash and cash equivalents were $1,023,789, total assets were $36,436,970 and total liabilities were $10,723,608. Current liabilities totaled $10,508,521, including a $6,881,250 Repurchase Forbearance liability. The balance sheet listed 1,152,607 ordinary shares issued and outstanding as of June 30, 2026, versus 26,736 as of December 31, 2025.

0 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 1 point

How the balance works

Positive

• None.

Negative

• Major pointSix-month net result: $8,079,392 loss, versus $698,032 income.

Filing Explained

Form 6-K furnishes interim information; for the six months ended June 30, 2026, $3,990,911 in net other expenses accompanied a $3,547,412 operating loss, while the year-earlier period’s $4,062,303 in net other income offset a $3,240,376 operating loss.

Key Figures

Revenue: $1,924,881 Gross profit: $464,488 Net loss: $8,079,392 +5 more

8 metrics

Revenue $1,924,881 Six months ended June 30, 2026; $2,019,628 for the six months ended June 30, 2025

Gross profit $464,488 Six months ended June 30, 2026; $313,804 for the six months ended June 30, 2025

Net loss $8,079,392 Six months ended June 30, 2026; net income was $698,032 for the six months ended June 30, 2025

Cash and cash equivalents $1,023,789 As of June 30, 2026

Total liabilities $10,723,608 As of June 30, 2026

Current liabilities $10,508,521 As of June 30, 2026

Repurchase Forbearance liability $6,881,250 As of June 30, 2026

Ordinary shares issued and outstanding 1,152,607 shares As of June 30, 2026; 26,736 shares as of December 31, 2025

Key Terms

Repurchase Forbearance liability, Embedded derivative liability, Right-of-use assets, Non-controlling interests

4 terms

Repurchase Forbearance liability financial

"Repurchase Forbearance liability"

Embedded derivative liability financial

"Embedded derivative liability"

Right-of-use assets financial

"Right-of-use assets, net"

Right-of-use assets are the rights a company gains to use a physical space or equipment under a lease agreement. They are recorded as assets on the company's balance sheet, reflecting the value of future benefits from the leased item. For investors, these assets provide a clearer picture of a company's obligations and resources related to leasing arrangements, helping to assess its financial health and operational commitments.

Non-controlling interests financial

"Non-controlling interests"

An ownership stake in a subsidiary held by outside shareholders rather than the parent company, representing the portion of that subsidiary’s assets and profits the parent does not control. For investors, it shows what part of consolidated earnings and equity belongs to others — like a roommate who owns part of a house — which affects how much value and profit per share are truly attributable to the parent company’s shareholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue did NIVF report for the six months ended June 30, 2026?

NIVF reported $1,924,881 in revenue for the six months ended June 30, 2026, compared with $2,019,628 for the six months ended June 30, 2025.

Did NIVF report a profit for the six months ended June 30, 2026?

No. NIVF reported a net loss of $8,079,392, compared with net income of $698,032 for the six months ended June 30, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 04:01 PM Accepted by SEC EDGAR 10/07/2026 - 04:01 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-42004

NEWGENIVF GROUP LIMITED

36/39-36/40, 13th Floor, PS Tower

Sukhumvit 21 Road (Asoke)

Khlong Toei Nuea Sub-district

Watthana District, Bangkok 10110

Thailand

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

EXPLANATORY NOTE

NewGenIvf Group Limited (the “Company”) is furnishing this report on Form 6-K to provide its unaudited condensed consolidated balance sheet as of June 30, 2026 and its unaudited condensed consolidated statement of operations and comprehensive (loss) income for the six months ended June 30, 2026. These unaudited condensed consolidated financial statements are furnished herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit No.		Description
99.1		NewGen Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 7, 2026

	NewGenIvf Group Limited
	By:	/s/ Wing Fung Alfred Siu
	Name:	Wing Fung Alfred Siu
	Title:	Chairman of the Board and Director

2

Exhibit 99.1

NEWGENIVF GROUP LIMITED
UNAUDITED CONSOLIDATED BALANCE SHEETS

(Stated in US Dollars)

		June 30,				December 31,
		2026				2025
ASSETS		(unaudited)				(audited)
Current assets
Cash and cash equivalents		$	1,023,789			$	758,621
Accounts receivable, net			115,970				166,531
Inventories			351,366				335,360
Deposits, prepayments and other receivables, net			4,482,625				503,588
Deposit for land acquisition			4,714,749				4,614,749
Deposit with a digital asset trading platform			4,717				34,987
Deposit with futures broker, net			—				59,369
Receivable from agents, net			392,876				794,116
Deferred offering costs			40,754				116,250
Total current assets			11,126,846				7,383,571
Non-current assets
Plant and equipment, net			1,733,832				1,789,110
Right-of-use assets, net			473,732				504,192
Intangible assets			21,415,893				21,415,069
Digital asset, at fair value			—				1,630,827
Investment in equity securities			1,686,667				—
Total non-current assets			25,310,124				25,339,198
TOTAL ASSETS		$	36,436,970			$	32,722,769
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Accounts payable		$	878,108			$	779,280
Accrued liabilities and other payables			500,236				711,892
Contract liabilities			105,835				111,981
Due to related parties			64,481				6,421
Operating lease liabilities, current			263,532				238,105
Convertible notes			1,104,543				256,056
Embedded derivative liability			710,536				262,616
Repurchase Forbearance liability			6,881,250				—
Total current liabilities			10,508,521				2,366,351
Non-current liabilities
Operating lease liabilities, non-current			215,087				272,359
Convertible notes, non-current			--				4,097,366
Total non-current liabilities			215,087				4,369,725
Total liabilities		$	10,723,608			$	6,736,076
Shareholders’ equity
Ordinary shares, no par value, unlimited authorized shares and 1,152,607* and 26,736* shares issued and outstanding as of June 30, 2026 and December 31, 2025 respectively			—				—
Additional paid-in capital			25,786,740				17,881,176
Retained Earnings / (Accumulated deficit)			857,860				8,893,414
Accumulated other comprehensive (loss) income			(215,658	)			(143,071	)
Equity attributable to the shareholders of the Company			26,428,942				26,631,519
Non-controlling interests			(715,580	)			(644,826	)
Total shareholders’ equity			25,713,362				25,986,693
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$	36,436,970			$	32,722,769

* The shares as presented have been adjusted retrospectively for Reverse Share Splits effected in January 2026 of 1 share for every 3 existing shares issued, in March 2026 of 1 share for every 4 existing share issued, in July 2026 of 1 share for every 3 shares issued and in September 2026 of 1 share for every 3 shares issued respectively.

2

NEWGENIVF GROUP LIMITED
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND

COMPREHENSIVE (LOSS) INCOME
(Stated in US Dollars)

Six Months Ended

		June 30, 2026				June 30, 2025
Revenues		$	1,924,881			$	2,019,628
Cost of revenues			(1,460,393	)			(1,705,824	)
Gross profit			464,488				313,804
Operating expenses
Selling and marketing expenses			(416,238	)			(307,176	)
General and administrative expenses			(3,595,662	)			(3,247,004	)
Total operating expenses			(4,011,900	)			(3,554,180	)
Operating income (loss)			(3,547,412	)			(3,240,376	)
Other income (expenses), net
Other income (expenses), net			(3,990,911	)			4,062,303
Interest income			64				1,594
Interest expense			(541,133	)			(357,551	)
Total other income (expenses), net			(8,079,392	)			(3,938,408	)
Income (loss) before taxes			(8,079,392	)			698,032
Provision for income taxes			---				---
Net income (loss)			(8,079,392	)			698,032
Less: net loss attributable to non-controlling interests			(44,086	)			(26,943	)
Net income (loss) attributable to the shareholders of the Company		$	(8,035,306	)			724,975
Other comprehensive (loss) income
Foreign currency translation adjustment			(99,506	)			(66,526	)
Total comprehensive income (loss)			(8,178,898	)			631,506
Less: total comprehensive loss attributable to non-controlling interests			(70,754	)			(54,536	)
Total comprehensive income (loss) attributable to the shareholders of the Company		$	(8,108,144	)			686,042
Earning per share – basic		$	(26.64	)			1,418.76
Basic weighted average shares outstanding*			301,584				511

* The shares as presented have been adjusted retrospectively for Reverse Share Splits effected in January 2026 of 1 share for every 3 existing shares issued, in March 2026 of 1 share for every 4 existing share issued, in July 2026 of 1 share for every 3 shares issued and in September 2026 of 1 share for every 3 shares issued respectively.

3

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 NEWGEN REPORTS UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 202 57.0 KB